Company / Accounts Receivable
InMed Pharmaceuticals Inc. Accounts Receivable History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$465.1K
FY2025
5-year range
$88.0K / $465.1K
FY2022-FY2025
Trend
+31.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 3 consecutive years, from $88,027 in FY2022 to $465,104 in FY2025.
Based on SEC 10-K filings.
$465,104 in FY2025 with a 3-year CAGR of +74.2%.
Improved from $260,399 to $465,104 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +74.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- InMed Pharmaceuticals Inc.'s accounts receivable has grown for 3 consecutive years.
- 3-year CAGR of +74.2%, indicating consistent growth.
- In FY2025, accounts receivable increased 31.8% year-over-year.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $465.1K | +31.8% |
| FY2024 | $352.8K | +35.5% |
| FY2023 | $260.4K | +195.8% |
| FY2022 | $88.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026